Contemporary issues in the treatment of Alzheimer's disease: Tangible benefits of current therapies

Journal of Clinical Psychiatry

Volumn 67, Issue SUPPL. 3, 2006, Pages 15-22

  Tariot, Pierre N ^a  

^a BANNER ALZHEIMER S INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; CHOLINESTERASE INHIBITOR; DONEPEZIL; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NOOTROPIC AGENT; RIVASTIGMINE; SELEGILINE;

ALZHEIMER DISEASE; BEHAVIOR; CAREGIVER; CLINICAL TRIAL; COGNITION; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; HUMAN; MONOTHERAPY; NURSING CARE; NURSING HOME; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SYMPTOMATOLOGY;

ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; DOUBLE-BLIND METHOD; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; MEMANTINE; NEUROPROTECTIVE AGENTS; NURSING HOMES; PATIENT TRANSFER; PSYCHIATRIC STATUS RATING SCALES; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, N-METHYL-D-ASPARTATE; SELEGILINE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VITAMIN E;

EID: 33645471999     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Feldman H, Gracon S. Alzheimer's disease: symptomatic drugs under development. In: Gauthier S, ed. Clinical Diagnosis and Management of Alzheimer's Disease. Boston, Mass: Butterworth-Heinemann; 1996:239-259
2. Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. N Engl J Med 1997;336:1216-1222
3. Galasko D. An integrated approach to the management of Alzheimer's disease: assessing cognition, function and behaviour. Eur J Neurol 1998;5: S9-S17
4. Galasko D, Edland SD, Morris JC, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD), pt 11: clinical milestones in patients with Alzheimer's disease followed over 3 years. Neurology 1995;45:1451-1455
5. Feldman H, Gauthier S, Hecker J, et al. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 2001;57:613-620
6. Tariot PN, Cummings JL, Katz IR, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. J Am Geriatr Soc 2001;49:1590-1599
7. Danysz W, Parsons CG, Möbius HJ, el al. Neuroprotective and symptomatological action of memantine relevant for Alzheimer's disease: a unified glutamatergic hypothesis on the mechanism of action. Neurotox Res 2000;2:85-97
8. Reisberg B, Doody R, Stöffler A, et al. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003;348:1333-1341
9. 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry 1999;14:135-146
10. Ferm L. Behavioural activities in demented geriatric patients: study based on evaluations made by nursing staff members and on patients' scores on a simple psychometric test. Gerontol Clin (Basel) 1974;16:185-194
11. Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004;291:317-324
12. Beeri MS, Werner P, Davidson M, et al. The cost of behavioral and psychological symptoms of dementia (BPSD) in community dwelling Alzheimer's disease patients. Int J Geriatr Psychiatry 2002;17:403-408
13. Mega MS, Cummings JL, Fiorello T, et al. The spectrum of behavioral changes in Alzheimer's disease. Neurology 1996;46:130-135
14. Ballard C, Lowery K, Powell I, et al. Impact of behavioral and psychological symptoms of dementia on caregivers. Int Psychogeriatr 2000;12(suppl 1):93-105
15. Shin IS, Carter M, Masterman D, et al. Neuropsychiatric symptoms and quality of life in Alzheimer disease. Am J Geriatr Psychiatry 2005;13:469-474
16. Wolstenholme J, Fenn P, Gray A, et al. Estimating the relationship between disease progression and cost of care in dementia. Br J Psychiatry 2002;181:36-42
17. Phillips VL, Diwan S. The incremental effect of dementia-related problem behaviors on the time to nursing home placement in poor, frail, demented older people. J Am Geriatr Soc 2003;51:188-193
18. O'Brien JA, Shomphe LA, Caro JJ. Behavioral and psychological symptoms in dementia in nursing home residents: the economic implications. Int Psychogeriatr 2000;12:51-57
19. Aupperle PM, Koumaras B, Chen M, et al. Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer's disease: results of a 52-week open-label study. Curr Med Res Opin 2004;20:1605-1612
20. Wood S, Cummings JL, Hsu MA, et al. The use of the Neuropsychiatric Inventory in nursing home residents: characterization and measurement. Am J Geriatr Psychiatry 2000;8:75-83
21. Gauthier S, Wirth Y, Stöffler A, et al. Behavioural benefit by memantine treatment in moderate to severe Alzheimer's disease. Presented at the XXIV CINP Congress; June 20-24, 2004; Paris, France
22. Cummings JL, van Dyck C, Schmitt F, et al. Functional and behavioral effects of memantine in Alzheimer's disease. Presented at the 56th annual meeting of the American Academy of Neurology; April 24-May 1, 2004; San Francisco, Calif
23. Alexopoulos GS, Jeste DV, Chung H, et al. The Expert Consensus Guideline Series: treatment of dementia and its behavioral disturbances. Postgrad Med 2005; Spec Rpt:1-111
24. Mittelman MS, Ferris SH, Shulman E, et al. A family intervention to delay nursing home placement of patients with Alzheimer disease: a randomized controlled trial. JAMA 1996;276:1725-1731
25. Steele C, Rovner B, Chase GA, et al. Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease. Am J Psychiatry 1990;147:1049-1051
26. Cohen CA, Gold DP, Shulman KI, et al. Factors determining the decision to institutionalize dementing individuals: a prospective study. Gerontologist 1993;33:714-720
27. Lopez OL, Becker JT, Wisniewski S, et al. Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease. J Neurol Neurosurg Psychiatry 2002;72:310-314
28. Geldmacher DS, Provenzano G, McRae T, et al. Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease. J Am Geriatr Soc 2003;51:937-944
29. Courtney C, Farrell D, Gray R, et al. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 2004;363:2105-2115
30. Schneider LS. AD2000: donepezil in Alzheimer's disease [comment]. Lancet 2004;363:2100-2101
31. Wimo A, Winblad B, Stöffler A, et al. Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease. Pharmacoeconomics 2003;21:327-340